Bevacizumab Treatment and Retinal Vessel Monitoring

Technische Universität Dresden20 enrolled

Overview

Bevacizumab might influence the dynamic vessel function after being administered intravenously.

By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cancer

Interventions

bevacizumab treatmentDRUG

single infusion 10 mg/kg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients who wish and need bevacizumab treatment for underlying disease Exclusion Criteria: * previous bevacizumab treatment * known eye disease, eye surgery or eye trauma in history * myopia \>-2.0 dpt * hyperopia \> +2.0 dpt. * relevant media opacity of the lens * acute heart disease, ischemic insult, proven coronary heart disease * cardiac arrhythmia or vessel anomalies * seizure disorder or episode in history * migraine * treatment with corticosteroids within 4 weeks before study inclusion * intake of vasoactive drugs like AT-1 or glitazone * pregnancy

Locations (1)

Autonomic lab (ANF)

Dresden, Saxony, Germany

Outcomes

Primary Outcomes

Diameter of retinal vessels and dynamic vessel reaction

Time frame: Measurements before and after administration

Secondary Outcomes

Baroreflex sensitivity, heart frequence variability, reaction to handgrip test

Time frame: Measurements before and after administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.